---
title: "肿瘤微环境中的B细胞"
date: 2024-12-15T12:53:42Z
draft: ["false"]
tags: [
  "fetched",
  "MetaSpine"
]
categories: ["Acdemic"]
---
肿瘤微环境中的B细胞 by MetaSpine
------
<div><section data-tool="mdnice编辑器" data-website="https://www.mdnice.com"><h1 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">肿瘤微环境中的B细胞</span></span><span></span></h1><p data-tool="mdnice编辑器"><span leaf="">单细胞分析中B细胞的部分的结果不会解读，论文也学不出来，很多非泛癌B细胞的论文对其探讨也非常少。遂阅读综述。</span></p><p data-tool="mdnice编辑器"><span leaf="">本文是由位于加拿大温哥华的不列颠哥伦比亚大学（University of British Columbia）医学遗传学系的Céline M. Laumont和Brad H. Nelson撰写，并于2023年3月在</span><em><span leaf="">Cancer Cell</span></em><span leaf="">杂志上发表,论文题目为B cells in the tumor microenvironment:Multi-faceted organizers, regulators,and effectors of anti-tumor immunity。</span></p><figure data-tool="mdnice编辑器"><span leaf=""><img data-imgfileid="100001271" data-src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KVRK3dHPEjvUKmO4wSx33bppjS9ibNsiaFS8dfy5hiaRx9icQanMhW24X5g/640?wx_fmt=jpeg&amp;from=appmsg" data-type="jpeg" src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KVRK3dHPEjvUKmO4wSx33bppjS9ibNsiaFS8dfy5hiaRx9icQanMhW24X5g/640?wx_fmt=jpeg&amp;from=appmsg"></span></figure><figure data-tool="mdnice编辑器"><span leaf=""><img data-imgfileid="100001272" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KB5aUEKgTG8CK4RUqOUDibG8CIKMtjECDoBf05YBnjJXMLuicWZt0flfQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KB5aUEKgTG8CK4RUqOUDibG8CIKMtjECDoBf05YBnjJXMLuicWZt0flfQ/640?wx_fmt=png&amp;from=appmsg"></span></figure><figure data-tool="mdnice编辑器"><span leaf=""><img data-imgfileid="100001268" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KDgd5iaWtvADRagY77HyuxdQtMmMPE9kwYcEJb1SwWWqom3vfEtibabhA/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KDgd5iaWtvADRagY77HyuxdQtMmMPE9kwYcEJb1SwWWqom3vfEtibabhA/640?wx_fmt=png&amp;from=appmsg"></span></figure><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">目录</span></span><span></span></h2><p data-tool="mdnice编辑器"><span leaf="">一. B细胞的激活与耐受机制 二. 肿瘤浸润B细胞(TIL-Bs)的特点</span></p><ol><li><section><span leaf="">亚型与表型</span></section></li><li><section><span leaf="">抗原特异性(Antigenic specificities)</span></section></li><li><section><span leaf="">TIL-Bs与预后</span></section></li></ol><p data-tool="mdnice编辑器"><span leaf="">三. 与TIL-Bs反应相关的结构</span></p><ol><li><section><span leaf="">三级淋巴结构(TLSs)</span></section></li><li><section><span leaf="">淋巴-髓系聚集体(LMAs)</span></section></li></ol><p data-tool="mdnice编辑器"><span leaf="">四. TIl-Bs与基质的相互作用</span></p><ol><li><section><span leaf="">影响T和B细胞浸润的基质因子</span></section></li><li><section><span leaf="">基质在TLSs和LMAs形成与功能中的作用</span></section></li><li><section><span leaf="">基质对TIL-B表型和功能的影响</span></section></li></ol><p data-tool="mdnice编辑器"><span leaf="">五. TIL-B在抗瘤免疫中的多种机制</span></p><ol><li><section><span leaf="">TIL-Bs是TLS、LMA的诱导和组成者</span></section></li><li><section><span leaf="">TIL-Bs是抗原呈递细胞</span></section></li><li><section><span leaf="">TIL-Bs是抗体工厂</span></section></li><li><section><span leaf="">TIL_Bs也是抗瘤免疫的抑制细胞</span></section></li></ol><p data-tool="mdnice编辑器"><span leaf="">六. TIL-B、基质成分与治疗</span></p><ol><li><section><span leaf="">标准疗法</span></section></li><li><section><span leaf="">检查点抑制</span></section></li><li><section><span leaf="">疫苗</span></section></li><li><section><span leaf="">血管生成调节</span></section></li><li><section><span leaf="">细胞因子和趋化因子的递送</span></section></li><li><section><span leaf="">增强B细胞的抗原呈递作用</span></section></li><li><section><span leaf="">TIL-Bs来源的抗体</span></section></li><li><section><span leaf="">抑制Breg的活性</span></section></li></ol><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">B细胞的激活与耐受机制</span></span><span></span></h2><p data-tool="mdnice编辑器"><span leaf="">不同于T细胞，B细胞的发生与成熟均于骨髓中完成。</span></p><ol><li><section><span leaf="">中枢耐受的机制: 克隆缺失和受体编辑(clonal deletion and receptor editing)。</span></section></li><li><section><span leaf="">中枢耐受的结果: 从immature B细胞中去除自我反应性的B细胞。</span></section></li><li><section><span leaf="">外周耐受: 然而，外周血中仍有20%的自我反应性B细胞,。 (1) 用处：防止病原体通过模拟自身抗原来逃避监视； (2) 如何防止攻击自身: 免疫无知-ignaorance(无应答)、免疫无能-anergy（难应答）、免疫抑制-suppression（被Treg等抑制）、克隆救赎(通过BCR editing降低自身反应性)。</span></section></li><li><section><span leaf="">B细胞的增殖与分化: (1) 生理: 二级淋巴结构，生发中心(somatic hypermutation, class switching)； (2) 病理: 滤泡外反应；extrafollicular responses</span></section></li></ol><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">肿瘤浸润B细胞(TIL-Bs)的特点</span></span><span></span></h2><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">亚型与表型</span></span><span></span></h3><ol><li><section><span leaf="">TIL-Bs表型上包含naive B到PCs的所有类型细胞，主要是记忆性B细胞、浆母细胞、浆细胞；可用免疫组化和流式鉴定【查参考论文10,16,44-48】。</span></section></li><li><section><span leaf="">双阴性B细胞/非典型记忆B细胞：TIL-Bs通常包含IgD-CD27-双阴的记忆性B细胞，与免疫衰老、自身抗体的产生和B细胞耗竭有关</span></section></li><li><section><span leaf="">Breg: 类似Treg，但没marker，目前只能用效应分子来鉴定，如IL-10、IL-35、TGF-β；</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">抗原特异性(Antigenic specificities)</span></span><span></span></h3><ol><li><section><span leaf="">TIL-B靶抗原的鉴定：报道了70种左右【查引文64】，主要是胞内的蛋白质。</span></section></li><li><section><span leaf="">分类: (1) 在肿瘤中下调，如MMP14，TSPAN7, MUC1; (2)肿瘤睾丸抗原；（3）在肿瘤中未报道过的自身蛋白，如ADAMTS9; (4) 肿瘤病毒蛋白(oncoviral proteins); (5) 常见突变的蛋白,如TP53,BRCA2；(6) 谱系限制性蛋白，如BDNF, MLANA; (7)肿瘤相关转录后修饰蛋白,如β-actin，HSP70;</span></section></li><li><section><span leaf="">分泌自身反应性抗体的TIL-B的来源: (1)本身就具有自身反应性的CDR3序列；(2) 通过体细胞高频突变获得自身反应性，这也说明在肿瘤中有的TIL-Bs可以通过阳性选择;<img data-imgfileid="100001269" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0Ks253iapTektQiahHgY9wicxBibelrYmxfChJ0woh11QDxH4WjlzmJaz6xA/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0Ks253iapTektQiahHgY9wicxBibelrYmxfChJ0woh11QDxH4WjlzmJaz6xA/640?wx_fmt=png&amp;from=appmsg"></span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">TIL-Bs与预后</span></span><span></span></h3><ol><li><section><span leaf="">TIL-Bs与预后有关，但好坏癌种差异大，TCGA中也有报道【引文64，看一下marker】</span></section></li><li><section><span leaf="">预后价值与TIL-Bs在肿瘤微环境中的位置、Ig亚型有关系</span></section></li></ol><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">与TIL-Bs反应相关的结构</span></span><span></span></h2><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">三级淋巴结构(TLSs)</span></span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">三级淋巴结构是一种淋巴结样的异位淋巴器官。</span></p><ol><li><section><span leaf="">位置: TLS多见于热肿瘤的瘤周间质区域；</span></section></li><li><section><span leaf="">结构: TLS至少包含两个结构：（1）T细胞区，包含CD4+ T, CD8+ T, LAMP+ DC,  high-endothelial venules (HEVs)；（2）B细胞区: follicular DCs(FDCs)形成的网络和CD20+ B细胞；结构不全的称为immature TLSs。</span></section></li><li><section><span leaf="">GCs: germinal centers (GCs)-生发中心，可以支持B细胞的分化、亲和力成熟和类别转换；初级TLS无GC，次级TLS有GC，</span></section></li><li><section><span><span leaf="">TLS通常与预后正相关</span></span><span leaf="">，且瘤内的强于瘤周，次级的优于初级和未成熟的，后者反应了GC的重要性。</span></section></li><li><section><span leaf="">与刺激淋巴器官相比，TLS的优势: (1)位置上，更接近肿瘤细胞，可以更好的接受抗原。同时，也更容易被调节(正向或负向)，这可能也是没有明暗区的原因；（2）结构上，无被膜，更易形成抗原库；<img data-imgfileid="100001270" data-src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KwwypHGGhKgh9o5mmPzvpftibJc2dicSm2M6lBexymibvyhlmJrNFuRD2g/640?wx_fmt=jpeg&amp;from=appmsg" data-type="jpeg" src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KwwypHGGhKgh9o5mmPzvpftibJc2dicSm2M6lBexymibvyhlmJrNFuRD2g/640?wx_fmt=jpeg&amp;from=appmsg"></span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">淋巴-髓系聚集体(LMAs)</span></span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">有的时候，不是所有的免疫细胞都能形成TLS这样的结构，有的免疫细胞的聚集也有不同的特点，这些结构被用一个涵盖性术语(umbrella term)描述——"lympho-myeloid aggregates (LMAs)"，包括滤泡外反应区(Extrafollicular response zones),抗瘤效应区(Anti-tumor effector zones)，浆细胞主导的聚集体(Plasma cell-dominated aggregates) 和上皮内B细胞(Intra-epithelial B cells)</span></p><h4 data-tool="mdnice编辑器"><span></span><span><span leaf="">Extrafollicular response zones</span></span><span></span></h4><ol><li><section><span leaf="">特点: (1)B细胞与Tph(PD-1 high, CXCR5 -)反应，而不是Tfh(PD-1 high, CXCR5 +).(2)存在CD27- memory B cells</span></section></li><li><section><span leaf="">预后：</span><span><span leaf="">Extrafollicular response zones通常与预后负相关</span></span><span leaf=""><img data-imgfileid="100001273" data-src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KQeBwWTnGyVQibp00gcOX3GRvNJO3OuIAHRI1Kib0U7crW54MiafkJGjFg/640?wx_fmt=jpeg&amp;from=appmsg" data-type="jpeg" src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KQeBwWTnGyVQibp00gcOX3GRvNJO3OuIAHRI1Kib0U7crW54MiafkJGjFg/640?wx_fmt=jpeg&amp;from=appmsg"></span></section></li></ol><h4 data-tool="mdnice编辑器"><span></span><span><span leaf="">Anti-tumor effector zones</span></span><span></span></h4><ol><li><section><span leaf="">特点: Cytotoxic T cells and macrophages富集，代表由TIL-B起源的细胞因子或抗体引起的肿瘤杀伤作用，包括antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP).<img data-imgfileid="100001276" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0Kd5YjJ5GuwiaYEYlJKcjJdnsv7ChBOq5jNqdZ3jNqAKB4Wia4fJ9EWb9A/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0Kd5YjJ5GuwiaYEYlJKcjJdnsv7ChBOq5jNqdZ3jNqAKB4Wia4fJ9EWb9A/640?wx_fmt=png&amp;from=appmsg"></span></section></li></ol><h4 data-tool="mdnice编辑器"><span></span><span><span leaf="">Plasma cell-dominated aggregates</span></span><span></span></h4><ol><li><section><span leaf="">浆细胞浸润为主</span></section></li><li><section><span leaf="">例子: 髓系乳腺癌，高密度浆细胞浸润，预后好。<img data-imgfileid="100001275" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0Kl625I4Lkr0KGgZmFyuYl617Qqib5HibXycqJhFIkBdpOq3Nu1prN5STA/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0Kl625I4Lkr0KGgZmFyuYl617Qqib5HibXycqJhFIkBdpOq3Nu1prN5STA/640?wx_fmt=png&amp;from=appmsg"></span></section></li></ol><h4 data-tool="mdnice编辑器"><span></span><span><span leaf="">Intra-epithelial B cells</span></span><span></span></h4><ol><li><section><span leaf="">特点：肿瘤上皮由CD20+ B细胞以松散的弥散性聚集体浸润，其中也含有CD4+和CD8+ T细胞和巨噬细胞</span></section></li><li><section><span leaf="">killer B cells: kill tumor cells via FAS/FAS ligand interaction170 and/or secretion of granzyme B (GZMB).</span></section></li><li><section><span leaf="">Breg: immunosuppressive</span></section></li></ol><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">TIl-Bs与基质的相互作用</span></span><span></span></h2><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">影响T和B细胞浸润的基质因子</span></span><span></span></h3><ol><li><section><span leaf="">肌成纤维细胞中的Col基因减少T和B的浸润，而增加髓系起源抑制细胞的招募；</span></section></li><li><section><span leaf="">但T和B的变化有时并不是一致的，这说明TIL-Bs浸润障碍可能存在一些其他的机制</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">基质在TLSs和LMAs形成与功能中的作用</span></span><span></span></h3><ol><li><section><span leaf="">次级淋巴结构的形成依赖于fifibroblastic reticular cells (FRCs)和FDCs</span></section></li><li><section><span leaf="">部分免疫细胞可以通过TNF-alpha和lymphotoxin-beta上调黏附分子(ICAM-1, VCAM-1)和细胞因子(CCL19,CCl21,CXCL13)，从而进一步招募免疫细胞。这种相互作用形成了独特的T,B区域。</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">基质对TIL-B表型和功能的影响</span></span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">研究很少，主要是负向调控</span></p><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">TIL-B在抗瘤免疫中的多种机制</span></span><span></span></h2><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">TIL-Bs是TLS、LMA的诱导和组成者</span></span><span></span></h3><ol><li><section><span leaf="">相关因子(TIL-B分泌): Lymphotoxin-a1b2,ICOS ligand (ICOSL),CD40,CCL3,CCL4,CCL5,and CXCL10</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">TIL-Bs是抗原呈递细胞</span></span><span></span></h3><ol><li><section><span leaf="">甚至优于DC和macrophage</span></section></li><li><section><span leaf="">APC: CD21lowCD86+ memory-like (IgD- CD27+) B cell</span></section></li><li><section><span leaf="">T细胞暴露于activated TIL-B(CD69+HLA-DR+CD27+CD21+)倾向于Th1分化，而暴露于exhausted TIL-B(CD69+HLA-DR+CD27-CD21-)则倾向于Treg分化</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">TIL-Bs是抗体工厂</span></span><span></span></h3><ol><li><section><span leaf="">TIL-Bs可以分泌抗瘤抗体(IgG,IgA)包裹肿瘤细胞，见于肾癌、软组织肉瘤、高级别粘液性卵巢癌，子宫内膜癌。</span></section></li><li><section><span leaf="">TIL-Bs来源的抗体可能在抗瘤免疫中有独特的作用，因为存在TIL-B 的抗体与血清抗体反应disconnect的现象。</span></section></li></ol><h4 data-tool="mdnice编辑器"><span></span><span><span leaf="">TIL-Bs起源的抗体对肿瘤细胞的直接效应</span></span><span></span></h4><ol><li><section><span leaf="">机制：antibody-dependent intracellular neutralization(ADIN):</span></section></li><li><section><span leaf="">已有研究: 肺癌细胞可以内化IgG，通过TRIM-21实现蛋白降解。卵巢癌细胞可以胞吞IgA，通过拮抗RAS通路，从而使肿瘤细胞对CD8+ T更敏感。</span></section></li><li><section><span leaf="">相反，宿主的抗体反应反而是促肿瘤的。淋巴结中B细胞分泌的IgG可以识别肿瘤细胞糖基化的HSP70，这引起肿瘤细胞CXCR4的上调，从而吸引肿瘤细胞（沿着SDF1α的梯度）进入淋巴结。</span></section></li></ol><h4 data-tool="mdnice编辑器"><span></span><span><span leaf="">TIL-Bs起源的抗体可作为先天免疫反应的激活剂</span></span><span></span></h4><ol><li><section><span leaf="">抗体不仅可以靶向抗原，也可以激发强烈的先天效应机制，包括补体依赖的细胞毒性(CDC)，抗体依赖性细胞胞吞（ADCP）和抗体依赖的细胞毒性(ADCC)。</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">TIL_Bs也是抗瘤免疫的抑制细胞</span></span><span></span></h3><ol><li><section><span leaf="">Breg: Il-10, Il-35, TGF-beta, PD-L1,PD-1, GZMB, ADO,GABA</span></section></li><li><section><span leaf="">黑色素瘤骨转移：PD-L1+ Breg抑制T细胞IFN-gamma的分泌;<img data-imgfileid="100001277" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KswYdh1phCibnFWzRqaqa62h65kknfywnQib14DzbHicsppdQFFZJsHzpQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KswYdh1phCibnFWzRqaqa62h65kknfywnQib14DzbHicsppdQFFZJsHzpQ/640?wx_fmt=png&amp;from=appmsg"></span></section></li></ol><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">TIL-B、基质成分与治疗</span></span><span></span></h2><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">标准疗法</span></span><span></span></h3><ol><li><section><span leaf="">治疗前TIL-Bs可以预测化疗反应，化疗也可以增加TIL-Bs；</span></section></li><li><section><span leaf="">放疗与TIL-Bs的关系还不明确</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">检查点抑制</span></span><span></span></h3><ol><li><section><span leaf="">TIL-Bs的存在与免疫检查点治疗反应正相关，且CD4,B缺一不可，暗示B细胞和Tfh之间的相互作用。</span></section></li><li><section><span leaf="">副作用:自身抗体的产生；</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">疫苗</span></span><span></span></h3><ol><li><section><span leaf="">肿瘤疫苗可以增加TLSs</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">血管生成调节</span></span><span></span></h3><ol><li><section><span leaf="">也可以增加TLS，但不是所有血管靶向的治疗都可以，而且有可能诱发Breg；</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">细胞因子和趋化因子的递送</span></span><span></span></h3><p data-tool="mdnice编辑器"><span leaf="">CCL21, TNF-a, IL-1b和CXCL13可以吸引T and B cells形成HEV+TLSs</span></p><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">增强B细胞的抗原呈递作用</span></span><span></span></h3><ol><li><section><span leaf="">目前靶向抗原呈递细胞的免疫疗法主要聚焦于DC，B也有前景。</span></section></li><li><section><span leaf="">暴露于CD40或TLR9激动剂的B细胞可以促进激活T细胞的能力</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">TIL-Bs来源的抗体</span></span><span></span></h3><ol><li><section><span leaf="">TIL-Bs来源的抗体可以通过ADCP/ADCC起抗肿瘤作用。</span></section></li><li><section><span leaf="">也存在CDC的机制，而CDC是既可能促癌也可能抑癌。</span></section></li></ol><h3 data-tool="mdnice编辑器"><span data-cacheurl="" data-remoteid=""></span><span></span><span><span leaf="">抑制Breg的活性</span></span><span></span></h3><ol><li><section><span leaf="">目前缺乏Breg的marker，所以抑制其转化相较于清除，更具有可行性。 Therapeutic manipulation of TIL-Bs and stromal components</span></section></li></ol><figure data-tool="mdnice编辑器"><span leaf=""><img data-imgfileid="100001278" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KRSYy8AsZ7oTDgKmbBjFQkZ4wrNLpO2FEkcLLmuy04ACNuSOJfo0dRw/640?wx_fmt=png&amp;from=appmsg" data-type="png" src="https://mmbiz.qpic.cn/sz_mmbiz_png/k5tBakZAsaR1Jspv6lFRMaiasoByQ1L0KRSYy8AsZ7oTDgKmbBjFQkZ4wrNLpO2FEkcLLmuy04ACNuSOJfo0dRw/640?wx_fmt=png&amp;from=appmsg"></span></figure><h2 data-cacheurl="" data-remoteid="" data-tool="mdnice编辑器"><span></span><span><span leaf="">笔者读后小结</span></span><span></span></h2><ol><li><section><span leaf="">以后可能用到的内容： (1) Breg的marker; (2)T细胞暴露于activated TIL-B(CD69+HLA-DR+CD27+CD21+)倾向于Th1分化，而暴露于exhausted TIL-B(CD69+HLA-DR+CD27-CD21-)则倾向于Treg分化; (3) B细胞的研究需要关注TLS,LMA；</span></section></li><li><section><span leaf="">其他: (1) TIL-Bs可以类比TIL-T，本身是个好东西，宿主的抗体反应反而是促肿瘤的。</span></section></li></ol></section><section><span leaf=""><br></span></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/GMtbGjNLnE7Vnh6M0bfFzw",target="_blank" rel="noopener noreferrer">原文链接</a>
